Vestcor Inc Buys New Stake in SIGA Technologies, Inc. (NASDAQ:SIGA)

Vestcor Inc purchased a new position in SIGA Technologies, Inc. (NASDAQ:SIGA) in the 4th quarter, Holdings Channel.com reports. The firm purchased 48,177 shares of the company’s stock, valued at approximately $290,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC acquired a new position in shares of SIGA Technologies in the 3rd quarter worth approximately $30,000. EP Wealth Advisors LLC bought a new stake in SIGA Technologies in the third quarter valued at $82,000. XTX Topco Ltd acquired a new position in SIGA Technologies during the third quarter worth $85,000. Bailard Inc. lifted its holdings in shares of SIGA Technologies by 31.5% during the fourth quarter. Bailard Inc. now owns 18,800 shares of the company’s stock valued at $113,000 after acquiring an additional 4,500 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of SIGA Technologies in the 3rd quarter valued at $120,000. Institutional investors own 55.40% of the company’s stock.

SIGA Technologies Stock Performance

SIGA opened at $5.63 on Tuesday. The firm has a market cap of $402.19 million, a price-to-earnings ratio of 4.69 and a beta of 0.98. The firm’s 50-day simple moving average is $5.96 and its 200-day simple moving average is $6.60. SIGA Technologies, Inc. has a twelve month low of $5.16 and a twelve month high of $12.83.

SIGA Technologies (NASDAQ:SIGA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported $0.63 earnings per share for the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. The firm had revenue of $81.40 million for the quarter. As a group, sell-side analysts anticipate that SIGA Technologies, Inc. will post 1.04 EPS for the current fiscal year.

SIGA Technologies Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.